The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2025 and 2024, respectively (in thousands, except share and per share amounts):


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net loss attributable to Adaptive Biotechnologies Corporation	$	(25,614	)	$	(46,222	)	$	(55,466	)	$	(93,729	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		152,082,284			147,414,095			150,646,632			146,600,811
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.17	)	$	(0.31	)	$	(0.37	)	$	(0.64	)

Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2025 and 2024, respectively, as they had an anti-dilutive effect:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Stock options outstanding		11,622,872		13,055,050		11,794,753		13,070,461
Nonvested restricted stock units outstanding		11,722,493		11,174,598		11,163,655		10,757,897
Nonvested performance-based restricted stock units outstanding		124,976		—		75,262		—
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		5,356,880		3,771,579		4,836,972		3,159,668
Total		28,827,221		28,001,227		27,870,642		26,988,026

13. Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders